News
ChroMedX hires Conductive to develop HemoPalm biosensor
2016-04-20 16:21 ET - News Release
Dr. Wayne Maddever reports
CHROMEDX CORP. ENGAGES CONDUCTIVE TECHNOLOGIES INC. FOR BIOSENSOR DEVELOPMENT PROGRAMME
ChroMedX Corp. has engaged Conductive Technologies Inc. (CTI) of York, Pa., to assist with biosensor development on the company's HemoPalm technology.
ChroMedX has previously reported on the collaboration with Polygenesis on the development of the biosensor system and associated components, which are key aspects of the HemoPalm system.
"We are pleased to announce that Conductive Technologies Inc. (CTI) of York, Pa., have now joined this collaborative program. Our biosensor development program with Polygenesis Corp. has progressed as expected with basic electronics being established and testing of biosensors currently taking place. CTI supplied the initial gold electrode array deposited on polymeric substrate to ChroMedX and is now fully engaged, developing production methods for the manufacture of the ion-specific electrodes," said Dr. Wayne Maddever, president and chief executive officer, ChroMedX.
A critical component in the production method is CTI's equipment and expertise for automatic deposition of minute volumes of liquid on tiny portions of the gold electrodes, which subsequently solidify to become ion-specific membranes.
Dr. Matthew Musho, president of Conductive Technologies, said: "We are pleased to be a part of this exciting development program with ChroMedX. CTI continually looks for new applications for its biosensor technology, and the HemoPalm system holds great promise as a diagnostic tool."
We seek Safe Harbor.
© 2016 Canjex Publishing Ltd. All rights reserved.